264 related articles for article (PubMed ID: 12270728)
1. Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen.
Lavigne MV; Castro M; Mateo N; Deluchi S; Atzori C; Piudo L; Calcagno M; Brero ML; Manghi M
Microbes Infect; 2002 Jul; 4(8):815-20. PubMed ID: 12270728
[TBL] [Abstract][Full Text] [Related]
2. Alternative diphtheria, tetanus and whooping cough immunization schedule to evoke a Th2 tetanus and a Th1 pertussis immune response.
Lavigne MV; Castro M; Andino J; Manghi M
Microbes Infect; 2004 Apr; 6(5):481-4. PubMed ID: 15109963
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of chosen parameters of immuno response in mice immunized with whole-cell or acellular pertussis vaccines and challenged with B. pertussis strains harbouring different ptxS1/prn allele genes combinations].
Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J
Med Dosw Mikrobiol; 2007; 59(2):137-47. PubMed ID: 17929411
[TBL] [Abstract][Full Text] [Related]
4. Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice.
Ryan M; Gothefors L; Storsaeter J; Mills KH
Dev Biol Stand; 1997; 89():297-305. PubMed ID: 9272363
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.
Roduit C; Bozzotti P; Mielcarek N; Lambert PH; del Giudice G; Locht C; Siegrist CA
Infect Immun; 2002 Jul; 70(7):3521-8. PubMed ID: 12065491
[TBL] [Abstract][Full Text] [Related]
6. [Cytokines induced by experimental anti-tetanus immunization. Vaccine formulation effect].
Castro M; Mateo N; Lavigne V; Deluchi S; Atzori C; Piudo L; Brero ML; Manghi M
Medicina (B Aires); 2002; 62(2):154-8. PubMed ID: 12038038
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
8. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
[TBL] [Abstract][Full Text] [Related]
9. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0.
Barnard A; Mahon BP; Watkins J; Redhead K; Mills KH
Immunology; 1996 Mar; 87(3):372-80. PubMed ID: 8778021
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.
Kang KR; Huh DH; Kim JA; Kang JH
BMC Immunol; 2021 Oct; 22(1):68. PubMed ID: 34641798
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine.
Ausiello CM; Lande R; Urbani F; Di Carlo B; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
J Infect Dis; 2000 Jun; 181(6):1989-95. PubMed ID: 10837180
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
13. Comparative trial to assess the reactogenicity of the diphtheria-tetanus-acellular pertussis (DTPa) vaccine plus Haemophilus influenzae type B (Hib) conjugate vaccine and that of the diphtheria-tetanus-whole cell pertussis (DTPw) vaccine plus Hib conjugate vaccine, administered in single injection a.
Calbo F; Dal-Ré R; Díez-Delgado J; Oña S; Sánchez-Prados F; García-Corbeira P;
Med Clin (Barc); 2002 Jan; 118(1):1-4. PubMed ID: 11803003
[TBL] [Abstract][Full Text] [Related]
14. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
[TBL] [Abstract][Full Text] [Related]
15. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
[TBL] [Abstract][Full Text] [Related]
16. Immune response to a Tdap booster in vertically HIV-infected adolescents.
Spina FG; Gouvea A; Succi RCM; Calanca F; Weckx LY; Terreri MT; Takano MAS; de Moraes-Pinto MI
Vaccine; 2018 Sep; 36(37):5609-5616. PubMed ID: 30087050
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
Ladhani SN; Andrews NJ; Southern J; Jones CE; Amirthalingam G; Waight PA; England A; Matheson M; Bai X; Findlow H; Burbidge P; Thalasselis V; Hallis B; Goldblatt D; Borrow R; Heath PT; Miller E
Clin Infect Dis; 2015 Dec; 61(11):1637-44. PubMed ID: 26374816
[TBL] [Abstract][Full Text] [Related]
18. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
[TBL] [Abstract][Full Text] [Related]
19. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.
Tran Minh NN; He Q; Ramalho A; Kaufhold A; Viljanen MK; Arvilommi H; Mertsola J
Pediatrics; 1999 Dec; 104(6):e70. PubMed ID: 10586004
[TBL] [Abstract][Full Text] [Related]
20. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
